Fingerprint change as a consequence of anticancer treatments: A systematic integrative review
Silvia Belloni(IRCCS Humanitas Research Hospital), Rosario Caruso(University of Milan), Cristina Arrigoni(University of Pavia), Gianluca Conte(IRCCS Policlinico San Donato), Paola Tiberio(Fondazione IRCCS Istituto Nazionale dei Tumori), Arianna Magon(IRCCS Policlinico San Donato), Rita De Sanctis(Humanitas University)
Cited by 1
Related Papers
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
|The Lancet Oncology|2017|493
‘Vaccine hesitancy’ among university students in Italy during the COVID-19 pandemic
|European Journal of Epidemiology|2020|446
Challenges in Using Circulating miRNAs as Cancer Biomarkers
|BioMed Research International|2015|264
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
|The Lancet Neurology|2021|260
Functional changes in Duchenne muscular dystrophy
|Neurology|2011|178